Seres Therapeutics
MCRB
123 hedge funds and large institutions have $594M invested in Seres Therapeutics in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 42 increasing their positions, 37 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
14% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 37
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
1% more capital invested
Capital invested by funds: $588M → $594M (+$5.84M)
1% more funds holding
Funds holding: 122 → 123 (+1)
0.06% less ownership
Funds ownership: 4.22% → 4.15% (-0.06%)
29% less call options, than puts
Call options by funds: $1.85M | Put options by funds: $2.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$7M |
| 2 |
Handelsbanken Fonder
Stockholm,
Sweden
|
+$4.33M |
| 3 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$2.98M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$2.85M |
| 5 |
Walleye Capital
New York
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$4.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.3M |
| 5 |
BlackRock
New York
|
-$1.14M |
MCRB Hedge Fund Activity: Q1 2023 in Review
123 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2023, worth a combined $594M — up 0.99% from $588M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new MCRB positions and 19 closed out — a net gain of 1 holder — while 42 added to existing stakes and 37 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $7M. The largest seller was Federated Hermes, cutting an estimated $15.2M.
- 123 institutional investors held Seres Therapeutics (MCRB) as of Q1 2023, up from 122 in Q4 2022.
- Funds reported $594M of Seres Therapeutics stock for Q1 2023, up 0.99% quarter-over-quarter.
- 20 funds opened new Seres Therapeutics positions in Q1 2023 and 19 closed out, a net change of +1 holder.
- The largest Seres Therapeutics buyer in Q1 2023 was Avoro Capital Advisors, an estimated $7M added.
- The largest Seres Therapeutics seller in Q1 2023 was Federated Hermes, an estimated $15.2M sold.
Based on aggregated 13F filings for Q1 2023.